Effects of Quercetin on plasma total antioxidant capacity, lipid peroxidation, blood pressure, inflammatory markers and disease activity in patients with Rheumatoid Arthritis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT138807252394N2

Enrollment

Registered

2010-03-13

Start date

2010-04-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Rheumatoid Arthritis. Condition 2: Rheumatoid arthritis. Seropositive rheumatoid arthritis Other rheumatoid arthritis

Interventions

Intervention 1: Quercetin supplement, 500 mg caps per day for 8 weeks. Intervention 2: placebo caps for 8 weeks.

Treatment - Drugs

Quercetin supplement, 500 mg caps per day for 8 weeks

placebo caps for 8 weeks

Eligibility

Sex/Gender

All

Age

19 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Willing to participate in study, Clinical diagnosis of AR (meeting the American college of rheumatology 1987 criteria), Ages between 19 – 70 years , No smoking or addiction , No drug type and dose fluctuation since 1 month prior to the study and during intervention period , Not having severe cardiovascular, hepatic, kidney, gastrointestinal, thyroid, parathyroid diseases, diabetes and inflammation, Not using medications except for AR conventional drugs, Not using antioxidant supplements during last month, No pregnancy or lactation Exclusion criteria: Compliance less than 70%, Disinclination to continue for cooperation, developing illnesses which need particular cures or interfere with intervention such as increasing the disease activity or trauma

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Total antioxidant capacity (TAC). Timepoint: 8 weeks. Method of measurement: colorimetric assay.;Hs-TNF-alpha. Timepoint: 8 weeks. Method of measurement: ELISA.;Hs- CRP. Timepoint: 8 weeks. Method of measurement: ELISA.;Ox-LDL. Timepoint: 8 weeks. Method of measurement: ELISA.;Malondialdehyde. Timepoint: 8 weeks. Method of measurement: chemical colorimetric.;Disease activity score- 28 joints(DAS-28). Timepoint: 8 weeks. Method of measurement: Physical examination.;Morning stiffness. Timepoint: 8 weeks. Method of measurement: question.;Blood pressure. Timepoint: 8 weeks. Method of measurement: sphyngomanometer.	—

Measure

Time frame

Total antioxidant capacity (TAC). Timepoint: 8 weeks. Method of measurement: colorimetric assay.;Hs-TNF-alpha. Timepoint: 8 weeks. Method of measurement: ELISA.;Hs- CRP. Timepoint: 8 weeks. Method of measurement: ELISA.;Ox-LDL. Timepoint: 8 weeks. Method of measurement: ELISA.;Malondialdehyde. Timepoint: 8 weeks. Method of measurement: chemical colorimetric.;Disease activity score- 28 joints(DAS-28). Timepoint: 8 weeks. Method of measurement: Physical examination.;Morning stiffness. Timepoint: 8 weeks. Method of measurement: question.;Blood pressure. Timepoint: 8 weeks. Method of measurement: sphyngomanometer.

—

Secondary

Measure	Time frame
Rheumatoid factor(RF). Timepoint: 8 weeks. Method of measurement: turbidometric assay.;Eritrocyte sedimentation rate(ESR). Timepoint: 8 weeks. Method of measurement: .	—

Countries

Iran (Islamic Republic of)

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026